Semaglutide microarray patch (VX-201) evaluated as needle-free alternative to subcutaneous injection

Obesity and overweight are global health challenges, often managed with GLP-1 receptor agonists like semaglutide. While highly effective, current semaglutide formulations primarily rely on subcutaneous (SC) injections, which can lead to patient discomfort, needle phobia, and reduced adherence to long-term treatment regimens. Developing alternative, non-invasive delivery methods is crucial to improve patient experience and compliance, potentially broadening access and impact of these vital medications. Microneedle array patches (MAPs) offer a promising solution for transdermal drug delivery, bypassing needles while ensuring systemic absorption.

This was a first-in-human, Phase 1 clinical study (VX-201-101) designed as a randomized, single-center, double-blind, two-period, cross-over trial. The study evaluated VX-201, a novel needle-free microarray patch (MAP) delivering semaglutide epi-intradermally, against traditional subcutaneous (SC) administration of semaglutide. The trial enrolled healthy overweight and obese participants to assess the safety, tolerability, and pharmacokinetics (PK) of the MAP delivery system. The primary objective was to compare the systemic exposure and safety profile of semaglutide delivered via VX-201 versus SC injection.

The provided abstract describes the design of the VX-201-101 study, a first-in-human Phase 1 clinical trial. It details the study's objective to evaluate the safety, tolerability, and pharmacokinetics of semaglutide delivered via a microarray patch (VX-201) compared to subcutaneous injection in healthy overweight and obese participants. However, the abstract does not report any specific findings, results, or numerical data regarding the efficacy, safety outcomes, or pharmacokinetic profiles observed during the study. Therefore, no quantitative results or statistical comparisons can be extracted from this abstract.